Clinical Trials Directory

Trials / Unknown

UnknownNCT01250782

Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Hospital Universitari Son Dureta · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Recent reports suggest that most beneficial results of glutamine have been obtained with the parenteral administration of high doses of glutamine (0.35 g/Kg/d) and in some special group of patients, such as traumatic patients. Nevertheless total parenteral nutrition is not often used in critically ill patients. The endovenous administration of the the dipeptide N(2)-L-alanyl-L-glutamine in trauma ICU patients can reduce the number of infections, ICU length of stay and mortality. This benefit can be achieved independently the type of nutrition (enteral or parenteral nutrition), being a pharmaconutrient.

Detailed description

Objective: To evaluate the efficacy of the endovenous administration endovenous glutamine to reduce the number of infectious complications, mortality and ICU length of stay in trauma ICU patients. To achieve this objective we have designed this pilot study to obtain the necessary data to design a bigger trial in the future. Other objectives include: * To evaluate the efficacy of glutamine in different patients regarding their severity: patients with an Injury Severity Score\> 25 and patients with lower plasma levels of glutamine. * To registry the possible adverse events of the endovenous administration of glutamine.

Conditions

Interventions

TypeNameDescription
DRUGGlutamine0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
DRUGPhysiological serum100 mL of physiological serum indistinguishable from active comparator

Timeline

Start date
2010-10-01
Primary completion
2012-09-01
Completion
2012-10-01
First posted
2010-12-01
Last updated
2010-12-01

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT01250782. Inclusion in this directory is not an endorsement.